March 22, 2007 – WiCON International Group, a leading business information publisher specializing in the Chinese pharmaceutical industry and market, announced today that the coverage of Pharma China, the most influential media and business intelligence source covering the Chinese pharmaceutical industry and market, will be expanded to provide pharma executives worldwide with more comprehensive coverage of the dynamic and complex marketplace without additional costs to our subscribers.

Our flagship product, Pharma China (a monthly business journal in PDF and Print), will expand its content volume by 25% in order to accommodate the increase of our in-depth news coverage and feature articles that analyze contemporary trends and issues.

We also launched a Premium Edition of Pharma China Weekly Alert which is available only to our paid subscribers (for any of our products).  This new product supplies our subscribers with intelligent summaries of the top news in each week with links to full text articles on our website. 

Founded by pharma executives for pharma executives, Pharma China is committed to bringing the pharmaceutical industry with products that deal with real-world business needs and challenges.

Our popular Pharma China Online (www.pharmachinaonline.com) will be completely upgraded in the second half of 2007 with the addition of multiple databases and services. Our existing subscribers will have the chance to test drive our beta versions.

Some of the new database products in our pipeline include: 1) Leading Pharma Company Monitor (with comprehensive and up-to-date coverage), 2) Deals Monitor (wide range of deals monitored, including M&A, OEM, R&D Outsourcing, Licensing), 3) Regulatory Monitor (this database will not only provide the latest regulatory changes, but also tracks the historical development of regulations), and 4) R&D Watch (a database that monitors innovative drug products in China).

For more information and a free PDF sample of Pharma China, please visit www.pharmachinaonline.com and/or contact:

 

James J. Shen